Mucoadhesive metronidazole benzoate

Drug Profile

Mucoadhesive metronidazole benzoate

Alternative Names: Metronidazole benzoate

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Tillotts Pharma
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Gastrointestinal motility disorders

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Gastrointestinal motility disorders (In volunteers) in Switzerland (PO) (NCT02911298)
  • 20 Sep 2016 Preclinical trials in Gastrointestinal motility disorders in Switzerland before September 2016 (PO)
  • 20 Sep 2016 Tillotts Pharma plans a phase I trial in Healthy volunteers(NCT02911298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top